CrownBio is a Cutting Edge Translational Technology Company Making Precision Medicine a Reality
CrownBio brings clarity to drug discovery around the world by helping biopharmaceutical companies solve some of today's most pressing challenges in oncology, inflammation, cardiovascular, and metabolic disease Drug Discovery.
Our premier Translational Platforms for cancer, inflammation, and metabolic disease help our clients accelerate their new drug development programs. CrownBio develops world-leading preclinical efficacy models and provides both in vitro and in vivo testing services. We are a global company with facilities across the world in the United States, United Kingdom, China, and Taiwan.
We Help our Clients Accelerate Drug Discovery, Gain Insight and De-Risk Ushering Candidates into the Clinic
As a comprehensive solution provider, CrownBio helps reveal the best clinical possibilities with our proprietary HuPrime®, HuKemia®, HuBase™, HuMark™, HuTrial™, and HuSignature™ platforms enabling the rapid translation of a lead compound into a successful clinical candidate. CrownBio's cutting-edge, proprietary, Translational Technology Platforms provide robust and scientifically sound end-to-end solutions for preclinical drug development.
The Premier Translational Platforms for Advanced Drug Discovery
From large-scale in vitro and in vivo efficacy studies of drug candidates, to running surrogate trials in tandem with human clinical trials, CrownBio's well-characterized Translational Platforms deliver comprehensive and catered solutions for biopharmaceutical companies. By providing the data needed to inform and accelerate oncology, inflammation, and cardiovascular and metabolic disease (CVMD) therapeutic development, CrownBio helps our clients make smarter decisions about their drug candidates.
With more experience than anyone in the industry, CrownBio's global resources help customers answer the most challenging questions about human biology.
CrownBio's portfolio of cutting edge technologies includes the world's largest commercial collection of validated patient-derived xenograft (PDX) models. At CrownBio we are seeking to recapitulate the diversity and complexity of human cancer biology in the laboratory.